Skip to main content

Dermatopathology in the Desert: Pragmatic Approach to Diagnostic Challenges

Original release date:
October 19, 2022
Access to this course expires on:  September 28, 2025 at 11:59 PM Pacific Time
CME 12.75

Course Description
The diagnosis of neoplastic and non-neoplastic disorders represents one of the most difficult diagnostic challenges in pathology. Errors in the interpretation of skin biopsies, especially in relation to melanocytic tumors, are one of the most frequent causes for litigation in surgical pathology. There are numerous pitfalls that diagnostic pathologists need to be aware of, including lack of relevant clinical information, sampling error and the wide morphologic spectrum of both inflammatory and neoplastic disorders, often showing overlapping findings and only subtle differentiating features. Accurate diagnosis is paramount to initiate the appropriate treatment. Join expert faculty as they focus on melanocytic tumor pathology, mesenchymal tumor pathology, cutaneous lymphomas and histiocytoses and inflammatory dermatoses.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Understand the wide morphologic spectrum of cutaneous tumors and associated diagnostic challenges
  • Learn about recent developments in dermatopathology
  • Learn to integrate clinical information and ancillary tests for a better and more precise diagnosis

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty and IM Coordinator reported relevant financial relationships:
  • Klaus Busam, MD: Advisory Board Member, Dermtech
  • Alejandro Ariel Gru, MD: Consultant: Seattle Genetics; Primary Investigator, CRISPR Therapeutics, Innate Pharma, StemLine Therapeutics

The following faculty reported no relevant financial relationships:Thomas Brenn, MD, PhD, FRCPath, Ryanne Ashley Brown, MD, MBA

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. View and print your certificate by clicking here.

USCAP members receive a discount on all e-Learning courses. Not A Member? Click Here to sign up today.